reports
Cartesian Therapeutics Announces FDA Special Protocol Assessment Agree...
Cartesian Therapeutics Announces FDA Special Protocol Assessment Agreement for Phase 3 AURORA Trial of Descartes-08 in Myasthenia Gravis Trial on track to commence in 1H25 FREDERICK, Md., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, today announced that it has received written agreement from the U.S. Food and Drug Administration (FDA) under the Special Protocol Assessment (SPA) process on the overall design of the Company’s planned Phase 3 AURORA...
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)...
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) MALVERN, Pa., Jan. 24, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Compensation Committee of the Board of Directors of TELA Bio approved inducement grants of restricted stock units covering 4,000 shares of its common stock to seven newly-hired employees, with a grant date of January 21, 2025 (the "Grant Date"). The restricted stock units were granted pu...
Cartesian Therapeutics Highlights Progress and 2025 Strategic Prioriti...
Cartesian Therapeutics Highlights Progress and 2025 Strategic Priorities Across Pipeline of mRNA Cell Therapies for Autoimmune Diseases Phase 3 AURORA trial of Descartes-08 in myasthenia gravis on track to commence in 1H25 Deepening responses observed over time in Descartes-08-treated participants in Phase 2b trial in myasthenia gravis; Safety profile continues to support outpatient administration based on updated data shared in December 2024 Phase 2 systemic lupus erythematosus (SLE) trial of Descartes-08 ongoing with expected data readout in 2H25 Cash resources expected to support pla...
Cartesian Therapeutics Announces New Employment Inducement Grants
Cartesian Therapeutics Announces New Employment Inducement Grants FREDERICK, Md., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapies for the treatment of autoimmune diseases, today announced the granting of inducement awards to three new employees. On January 2, 2025, the Company issued to these employees options to purchase an aggregate of 19,324 shares of the Company’s common stock with an exercise price of $16.93, the closing trading price of the Company’s common stock on t...
Cartesian Therapeutics Announces New Employment Inducement Grants
Cartesian Therapeutics Announces New Employment Inducement Grants FREDERICK, Md., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapies for the treatment of autoimmune diseases, today announced the granting of inducement awards to four new employees. On December 12, 2024, the Company issued to these employees options to purchase an aggregate of 25,602 shares of the Company’s common stock with an exercise price of $20.12, the closing trading price of the Company’s common stock on ...
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)...
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) MALVERN, Pa., Dec. 13, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Compensation Committee of the Board of Directors of TELA Bio approved inducement grants of restricted stock units covering 1,700 shares of its common stock to three newly-hired employees, with a grant date of December 11, 2024 (the "Grant Date"). The restricted stock units were granted p...
Cartesian Therapeutics Announces Positive Updated Results from Phase 2...
Cartesian Therapeutics Announces Positive Updated Results from Phase 2b Trial of Descartes-08 in Participants with Myasthenia Gravis and Outlines Design of Planned Phase 3 Trial Phase 3 AURORA trial on track to commence in 1H2025; Primary endpoint to assess proportion of Descartes-08-treated participants with myasthenia gravis demonstrating an MG-ADL improvement of ≥3 points at Month 4 relative to placebo Deepening responses observed over time in Phase 2b trial, with Descartes-08-treated participants observed to have a 5.5-point reduction in MG-ADL at Month 4 Durable responses observe...
Cartesian Therapeutics to Present Updated Data from Phase 2b Trial of ...
Cartesian Therapeutics to Present Updated Data from Phase 2b Trial of Descartes-08 in Patients with Myasthenia Gravis at the 2nd Annual Cell Therapy for Autoimmune Disease Summit Company to host conference call and webcast with key opinion leader on December 3, 2024, at 7:30 a.m. ET FREDERICK, Md., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, today announced that updated efficacy and safety data from the Phase 2b trial of Descartes-08 in patients...
TELA Bio to Participate in Piper Sandler’s 36th Annual Healthcare Conf...
TELA Bio to Participate in Piper Sandler’s 36th Annual Healthcare Conference MALVERN, Pa., Nov. 19, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will participate in Piper Sandler’s 36th Annual Healthcare Conference. TELA’s management is scheduled to present at Piper Sandler’s 36th Annual Healthcare Conference at 12:00 pm ET on December 3rd, 2024. Interested parties can access the live and archived webcast at . About TELA ...
- Dave Nicoski
- Ross LaDuke
Vital Signs: Actionable charts
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
HBI HANESBRANDS INC.
ESE ESCO TECHNOLOGIES INC.
DGX QUEST DIAGNOSTICS INCORPORATED
DAR DARLING INGREDIENTS INC.
FLR FLUOR CORPORATION
HWBK HAWTHORN BANCSHARES
CENX CENTURY ALUMINUM COMPANY
UEIC UNIVERSAL ELECTRONICS INC.
WEYS WEYCO GROUP INC.
PNRG PRIMEENERGY RESOURCES
TPB TURNING POINT BRANDS
SENEA SENECA FOODS CORP. CL A
AA ALCOA CORPORATION
LMB LIMBACH HOLDINGS
SRTS SENSUS HEALTHCARE
ATGE ADTALEM GLOBAL EDUCATION INC.
DESP DESPEGAR.COM CORP.
SMID SMITH MIDLAND
FGBI FIRST GUARANTY BANCSHARES
NVST ENVISTA HOLDINGS
AFRM AFFIRM HOLDINGS
SPNT SIRIUSPOINT LTD
LMND LEMONADE INC
PAY PAYMENTUS HLDGS INC
COIN COINBASE GLOBAL INC
RKLB ROCKET LAB USA INC
PPTA PERPETUA RESOURCES CORP
ROOT ROOT INC
LUNR INTUITIVE MACHINES INC
HIPO HIPPO HLDGS INC
BG BUNGE LIMITED
LB LANDBRIDGE COMPANY LLC
FOA FINANCE OF AMERICA COMPANIES INC.
HOYFY HUHTAMAKI (VAN LEER) OYJ ADR 144A
- Jonathan Moreland
LOGN LOGITECH INTERNATIONAL S.A.
TCBI TEXAS CAPITAL BANCSHARES INC.
RRGB RED ROBIN GOURMET BURGERS INC.
PPSI PIONEER POWER SOLUTIONS
PLAY DAVE & BUSTER'S ENTERTAINMENT INC.
OPK OPKO HEALTH INC.
NMFC NEW MOUNTAIN FINANCE CORPORATION
CROX CROCS INC.
AIN ALBANY INTERNATIONAL CORP. CLASS A
NSC NORFOLK SOUTHERN CORPORATION
ATLO AMES NATIONAL CORP.
TAYD TAYLOR DEVICES INC.
FBK FB FINANCIAL CORPORATION
CDZI CADIZ INC.
JELD JELD-WEN HOLDING INC.
RMCF ROCKY MOUNTAIN CHOCOLATE FACTORY INC.
MAV PIONEER MUNICIPAL HIGH INCOME ADVANTAGE TRUST
SNBR SLEEP NUMBER CORPORATION
ESQ ESQUIRE FINANCIAL HOLDINGS
MPB MID PENN BANCORP INC.
NWPP NEW PEOPLES BANKSHARES INC.
MEC MAYVILLE ENGINEERING
GRX THE GABELLI HEALTHCARE & WELLNESSRX TRUST
CCO CLEAR CHANNEL OUTDOOR HOLDINGS INC
TELA TELA BIO
ENX EATON VANCE NEW YORK MUNICIPAL BOND FUND
WSC WILLSCOT MOBILE MINI HOLDINGS CORP
BDSX BIODESIX
MODV MODIVCARE INC
UAN CVR PARTNERS LP
PFBX PEOPLES FINANCIAL CORP. (MISSISSIPPI)
TRIN TRINITY CAPITAL INC
BGS B&G FOODS
NRDS INC.
MAIA NERDWALLET INC
SKYH MAIA BIOTECHNOLOGY INC
MBLY SKY HARBOUR GROUP CORP
NE MOBILEYE GLOBAL INC
CALC NOBLE CORP (NEW)
BYON CALCIMEDICA INC.
DRUG BEYON 3D LTD
IKT BRIGHT MINDS BIOSCIENCES INC
ARR INHIBIKASE THERAPEUTICS INC.
MIO ARMOUR RESIDENTIAL REIT INC.
OI PIONEER MUN HIGH INCOME OPPORTUNITIES FD INC
WPC OWENS ILLINOIS INC.
UMAC W. P. CAREY AND CO. LLC
EVM UNUSUAL MACHS INC NEV
PDYN EATON VANCE INSD CALIF MUN BD FD
SARCOS TECHNOLOGY AND ROBOTICS CORP
Cartesian Therapeutics Announces New Employment Inducement Grants
Cartesian Therapeutics Announces New Employment Inducement Grants FREDERICK, Md., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapies for the treatment of autoimmune diseases, today announced the granting of inducement awards to two new employees. On November 4, 2024, the Company issued to these employees options to purchase an aggregate of 4,854 shares of the Company’s common stock with an exercise price of $19.11, the closing trading price of the Company’s common stock on the...
TELA Bio Reports Third Quarter 2024 Financial Results
TELA Bio Reports Third Quarter 2024 Financial Results Reiterates 2024 Revenue Guidance and Expects Recently Implemented Operational Efficiency Improvements to Reduce Operating Expenses in 2025 MALVERN, Pa., Nov. 07, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today reported financial results for the third quarter ended September 30, 2024. Recent Highlights Reported revenue of $19.0 million in the third quarter, representing growth of 26% over the prior year pe...
Cartesian Therapeutics Reports Third Quarter 2024 Financial Results an...
Cartesian Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update Company expects to commence Phase 3 trial of Descartes-08 in patients with myasthenia gravis in 1H2025 following recent meeting with U.S. Food and Drug Administration Presentation of updated efficacy and safety data from Phase 2b trial and Phase 3 trial design of Descartes-08 in patients with myasthenia gravis expected by year-end Dosing underway in Phase 2 trial of Descartes-08 in patients with systemic lupus erythematosus Dosing underway in first-in-human Phase 1 tr...
Cartesian Therapeutics Announces Presentation at the Upcoming 66th ASH...
Cartesian Therapeutics Announces Presentation at the Upcoming 66th ASH Annual Meeting FREDERICK, Md., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, today announced that safety and tolerability data from patients treated with Descartes-08 will be featured during a poster presentation at the upcoming 66th American Society of Hematology (ASH) Annual Meeting and Exposition, being held December 7-10, 2024 in San Diego. A copy of the abstract is available...
- Jonathan Moreland
LOGN LOGITECH INTERNATIONAL S.A.
TCBI TEXAS CAPITAL BANCSHARES INC.
RRGB RED ROBIN GOURMET BURGERS INC.
PPSI PIONEER POWER SOLUTIONS
MITK MITEK SYSTEMS INC.
GDOT GREEN DOT CORPORATION CLASS A
CROX CROCS INC.
CPSI COMPUTER PROGRAMS & SYSTEMS INC.
ANGO ANGIODYNAMICS INC.
DKL DELEK LOGISTICS PARTNERS
NSC NORFOLK SOUTHERN CORPORATION
EBF ENNIS
ATLO AMES NATIONAL CORP.
TAYD TAYLOR DEVICES INC.
RELL RICHARDSON ELECTRONICS LTD.
FBK FB FINANCIAL CORPORATION
AVK ADVENT CLAYMORE CONVERTIBLE SECURITIES & INCOME FUND
GATX GATX CORP
RMCF ROCKY MOUNTAIN CHOCOLATE FACTORY INC.
MAV PIONEER MUNICIPAL HIGH INCOME ADVANTAGE TRUST
RFIL RF INDUSTRIES LTD.
ZIVO ZIVO BIOSCIENCE
ANIX INC.
NFE ANIXA BIOSCIENCES
GRX NEW FORTRESS ENERGY
TELA THE GABELLI HEALTHCARE & WELLNESSRX TRUST
DYNR TELA BIO
CSU DYNARESOURCE INC.
MODV CAPITAL SENIOR LIVING
NUVB MODIVCARE INC
SMMT NUVATION BIO INC (A)
BMEA SUMMIT THERAPEUTICS INC
NRDS BIOMEA FUSION
TBBK INC.
BIGZ NERDWALLET INC
SKYH THE BANCORP
CALC INC.
BYON BLACKROCK INNOVATION AND GROWTH TST
SRFM SKY HARBOUR GROUP CORP
IKT CALCIMEDICA INC.
ENGN BEYON 3D LTD
APRE SURF AIR MOBILITY INC.
IDR INHIBIKASE THERAPEUTICS INC.
OCX ENGENE HOLDINGS INC
MIO APREA THERAPEUTICS INC
CLNN IDAHO STRATEGIC RESOURCES INC
SIRI ONCOCYTE CORPORATION
UMAC PIONEER MUN HIGH INCOME OPPORTUNITIES FD INC
VERB CLENE INC
SIRIUS XM HLDGS INC NEW
UNUSUAL MACHS INC NEV
VERB TECHNOLOGY COMPANY INC.
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)...
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) MALVERN, Pa., Nov. 01, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Compensation Committee of the Board of Directors of TELA Bio approved inducement grants of restricted stock units covering 5,400 shares of its common stock to six newly-hired employees, with a grant date of November 1, 2024 (the "Grant Date"). The restricted stock units were granted purs...
First Guaranty Bancshares, Inc. Announces Third Quarter 2024 Financial...
First Guaranty Bancshares, Inc. Announces Third Quarter 2024 Financial Results HAMMOND, La., Oct. 31, 2024 (GLOBE NEWSWIRE) -- First Guaranty Bancshares, Inc. ("First Guaranty") (NASDAQ: FGBI), the holding company for First Guaranty Bank, announced its unaudited financial results for the third quarter and nine months ending September 30, 2024. Financial Highlights for the third quarter and nine months ended September 30, 2024, are as follows: Total assets increased $371.2 million and were $3.9 billion at September 30, 2024 and $3.6 billion at December 31, 2023. Total loans at September ...
- Jonathan Moreland
MAN MANPOWERGROUP
TTSH TILE SHOP HOLDINGS INC.
TCBI TEXAS CAPITAL BANCSHARES INC.
RRGB RED ROBIN GOURMET BURGERS INC.
PPSI PIONEER POWER SOLUTIONS
MOFG MIDWESTONE FINANCIAL GROUP
MITK MITEK SYSTEMS INC.
KVHI KVH INDUSTRIES INC.
GDOT GREEN DOT CORPORATION CLASS A
CPSI COMPUTER PROGRAMS & SYSTEMS INC.
ANGO ANGIODYNAMICS INC.
AHH ARMADA HOFFLER PROPERTIES INC.
A0JMXQ INDIA CAPITAL GROWTH FUND LTD.
DKL DELEK LOGISTICS PARTNERS
NSC NORFOLK SOUTHERN CORPORATION
EBF ENNIS
RELL RICHARDSON ELECTRONICS LTD.
FBK FB FINANCIAL CORPORATION
AVK ADVENT CLAYMORE CONVERTIBLE SECURITIES & INCOME FUND
GATX GATX CORP
RMCF ROCKY MOUNTAIN CHOCOLATE FACTORY INC.
RFIL RF INDUSTRIES LTD.
ZIVO ZIVO BIOSCIENCE
ANIX INC.
INMB ANIXA BIOSCIENCES
NFE INMUNE BIO
TELA INC.
DYNR NEW FORTRESS ENERGY
CSU TELA BIO
VRDN DYNARESOURCE INC.
MODV CAPITAL SENIOR LIVING
NUVB VIRIDIAN THERAPEUTICS INC
CTLP MODIVCARE INC
SMMT NUVATION BIO INC (A)
BMEA CANTALOUPE
NRDS INC.
BHVN SUMMIT THERAPEUTICS INC
BIGZ BIOMEA FUSION
BUKS INC.
SRFM NERDWALLET INC
IKT BIOHAVEN LTD
ENGN BLACKROCK INNOVATION AND GROWTH TST
APRE BUTLER NATIONAL CORP
ASGI SURF AIR MOBILITY INC.
IDR INHIBIKASE THERAPEUTICS INC.
OCX ENGENE HOLDINGS INC
BNTC APREA THERAPEUTICS INC
CLNN ABERDEEN STANDARD GLOBAL INFRASTRUCTURE INCOME FUND
SIRI IDAHO STRATEGIC RESOURCES INC
ONCOCYTE CORPORATION
BENITEC BIOPHARMA INC
CLENE INC
SIRIUS XM HLDGS INC NEW
- Jonathan Moreland
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.